Micronutrient Therapy for Sepsis

Management of Sepsis: The Surviving Sepsis Guidelines for Early Therapy

Hospital Physician June 2007 21 Sepsis is a common condition that is associated with poor patient outcomes and high financial costs. An estimated 750,000 cases of sepsis occur each year. Because sepsis is more common in elderly patients, its incidence is expected to rise as the US population ages.1 Despite recent advances in management and therapy, the mortality rate from severe sepsis remains ...

Micronutrient therapy for chronic pancreatitis: premises and pitfalls.

The ‘ANTICIPATE’ trial professing the death knell for micronutrient antioxidant therapy in chronic pancreatitis was reported last September [1] and rubber-stamped by pundits [2, 3], but is flawed by misconception and wrong patient selection. In view of the six-month delay to publication of cautionary letters [4] and that misgivings were not allayed by the authors’ riposte [5], it might be helpf...

Micronutrient therapy for chronic pancreatitis: rationale and impact.

Micronutrient therapy, designed to buttress tissue methyl and thiol groups, curbs attacks and controls background pain in patients with chronic pancreatitis, irrespective of aetiology. This outcome and the premises upon which it is based facilitate an understanding of links with mutations in genes for hereditary pancreatitis and cystic fibrosis, demography, and predisposition to pancreatic canc...

Sepsis: Antimicrobial Therapy

Medication Therapy for Early-Onset Neonatal Sepsis.

S sepsis is a common cause of morbidity and mortality in neonates. In a population-based surveillance study1 from 2005 to 2008, researchers estimated that 3300 cases of early-onset sepsis (EOS) occur in the United States each year, with 390 of these cases resulting in death. The risk is highest in preterm neonates, which account for 1570 of the 3300 cases and 360 deaths.1 Despite its prevalence...